Metformin Treatment Modulates Long Non-Coding RNA Isoforms Expression in Human Cells.

Area of Science:

• Molecular Biology
• Genomics
• Pharmacology

Background:

• Long noncoding RNAs (lncRNAs) exhibit complex splicing and multiple isoforms, yet expression studies often focus solely on the gene level.
• Metformin, a primary treatment for type 2 diabetes, has a mechanism of action that is not fully elucidated, with transcriptomic studies typically analyzing protein-coding genes.

Purpose of the Study:

• To characterize metformin-affected lncRNA isoforms across various human cell types.
• To investigate the regulatory roles of differentially expressed (DE) lncRNA isoforms in response to metformin.
• To provide novel insights into the molecular mechanisms of metformin action.

Main Methods:

• Differential expression (DE) isoform analysis was performed on six metformin treatment series across human cancer and non-cancer cell lines.
• In silico tools were utilized to infer the potential biological functions of identified DE lncRNA isoforms.

Main Results:

• A specific lncRNA isoform (AC016831.6-205) was consistently highly expressed across all metformin treatment series, featuring an exon potentially encoding a peptide relevant to metformin's action.
• Two other lncRNA isoforms (ZBED5-AS1-207 and AC125807.2-201) were identified as potential cis-regulatory elements influencing nearby transcripts.

Conclusions:

• The study highlights the significance of analyzing lncRNA isoforms, not just genes, for a comprehensive understanding of metformin's molecular effects.
• Considering isoform-level changes in lncRNAs offers a deeper perspective on metformin's therapeutic mechanisms in metabolic diseases.